Quest Diagnostics Inc (DGX)

86.36
NYSE : Health Care
Prev Close 85.31
Day Low/High 85.08 / 86.44
52 Wk Low/High 59.66 / 86.44
Avg Volume 1.20M
Exchange NYSE
Shares Outstanding 139.02M
Market Cap 11.86B
EPS 4.90
P/E Ratio 14.91
Div & Yield 1.60 (1.90%)

Latest News

One In Two American Adults Misuse Their Prescription Drugs, Finds Analysis Of More Than Three Million Lab Tests From Quest Diagnostics

One In Two American Adults Misuse Their Prescription Drugs, Finds Analysis Of More Than Three Million Lab Tests From Quest Diagnostics

Study Finds Sharp Increase in Patients Who Combine Prescribed Medications with Other Drugs; Two in Three Users of Heroin Take it with Benzodiazepines, a Potentially Lethal Combination

Trade Idea: Quest Diagnostics

Try this risk reversal strategy in DGX.

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

Unsafe Lead Levels In Children Found In Numerous Regions Of The United States, Finds New Study In Journal Of Pediatrics

Unsafe Lead Levels In Children Found In Numerous Regions Of The United States, Finds New Study In Journal Of Pediatrics

Largest percentage of children with very high blood lead levels concentrated in six regions, including in New York, Pennsylvania and Ohio

New Study Of Physicians And Health Plan Executives Reveals Actions Needed To Accelerate Value-Based Care

New Study Of Physicians And Health Plan Executives Reveals Actions Needed To Accelerate Value-Based Care

HIGHLIGHTS FROM THE QUEST DIAGNOSTICS/INOVALON STUDY INCLUDE:

Jim Cramer -- 'The Real Market's Healthier,' So Ignore the Bears

Jim Cramer -- 'The Real Market's Healthier,' So Ignore the Bears

There is so much buying power in so many new areas.

Quest Diagnostics Becomes #40 Most Shorted S&P 500 Component, Replacing Dr Pepper Snapple Group

Quest Diagnostics Becomes #40 Most Shorted S&P 500 Component, Replacing Dr Pepper Snapple Group

The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards

Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards

Healthcare analytics technology from Quest Diagnostics and Inovalon connects with nearly 600 EHR platforms to provide actionable patient insights at the point of care

LabCorp and Quest Diagnostics Could Capitalize on Federal Investigation of Theranos

LabCorp and Quest Diagnostics Could Capitalize on Federal Investigation of Theranos

As VC-backed start-up Thernos is hampered by Federal investigations, rivals LabCorp and Quest Diagnostics should benefit.

Laboratory Corp. of America Looks Pretty Healthy

LH's $5.7B Covance takeover could be just what the doctor ordered.

One Year After Launch, BRCA Share™ Open Data Initiative Reveals New Findings On BRCA Gene Mutations Linked To Hereditary Breast And Ovarian Cancer Risk

One Year After Launch, BRCA Share™ Open Data Initiative Reveals New Findings On BRCA Gene Mutations Linked To Hereditary Breast And Ovarian Cancer Risk

Co-Founded by Quest Diagnostics and Inserm, with LabCorp as First Member, BRCA Share is now the Largest Open BRCA Datashare of Curated BRCA Variants Clinically Suitable for Patient Management

Quest Diagnostics Launches Three Genetic Test Panels For Predicting Hereditary Cancer Risk

Quest Diagnostics Launches Three Genetic Test Panels For Predicting Hereditary Cancer Risk

34-gene panel for assessing risk of 15 inherited cancers among new Quest Vantage™ test services to be highlighted during the 2016 ASCO Annual Meeting

Quest Diagnostics Becomes #49 Most Shorted S&P 500 Component, Replacing Consolidated Edison

Quest Diagnostics Becomes #49 Most Shorted S&P 500 Component, Replacing Consolidated Edison

The most recent short interest data has been released for the 05/13/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

These 5 Rocket Stocks Look Ready for Blastoff in May

These 5 Rocket Stocks Look Ready for Blastoff in May

These stocks have both short-term gain catalysts and longer-term growth potential.

Zika Test From Quest Diagnostics Authorized By The FDA For Emergency Use

Zika Test From Quest Diagnostics Authorized By The FDA For Emergency Use

First Test from a Commercial Lab to Receive Emergency Use Authorization for Testing Patients in the United States, including Puerto Rico, for Zika Infection

Analysts: Quest Likely to Do Deals First, Stock Buybacks Second, with Focus Sale Proceeds

Analysts: Quest Likely to Do Deals First, Stock Buybacks Second, with Focus Sale Proceeds

Quest Diagnostics in March agreed to sell Focus Diagnostics to DiaSorin SpA for $300 million.

Quest Diagnostics (DGX) Marked As A Barbarian At The Gate

Quest Diagnostics (DGX) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Quest Diagnostics (DGX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

New Diagnostic Pathways Could Improve Dementia Diagnosis, According To Consensus Statements To Be Presented At The American Academy Of Neurology Annual Meeting

New Diagnostic Pathways Could Improve Dementia Diagnosis, According To Consensus Statements To Be Presented At The American Academy Of Neurology Annual Meeting

Quest Diagnostics and UCSF will also present novel research on improving the quality and reducing the costs of dementia care